Drug intelligence / Profile preview

Qiaoruisu capsules

Development stage: Unknown
Lead developer: Hubei Furen Pharmaceutical
Administration: Oral

Overview

Qiaoruisu capsules is a Traditional Chinese Medicine (TCM) formulation developed by Hubei Furen Pharmaceutical. It is primarily indicated for the treatment of respiratory conditions characterized by phlegm-heat syndrome, which typically presents as cough, sputum production, and wheezing. These symptoms are often associated with acute bronchitis, acute exacerbations of chronic bronchitis, and other respiratory tract infections. The formulation is designed to clear heat, detoxify, and resolve phlegm. As of 2025, the drug is undergoing Phase IV post-marketing safety monitoring in China to further evaluate its safety profile in adult patients with these conditions.

Brand names: Qiaoruisu
Other names: 翘蕊苏胶囊Qiaoruisu jiaonang

Beyond the preview

Go deeper on Qiaoruisu capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiaoruisu capsules.

Explore the full profile